Hutchmed sets July 30, 2026 date for first-half financial results
The company will report interim 2026 results and hold webcasts in English and Putonghua the same week.
HUTCHMED (China) Limited said it will announce interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026, at 7:00 am Eastern Daylight Time, 12:00 noon British Summer Time, and 7:00 pm Hong Kong Time.1
Following the release, company management plans to hold two webcast presentations for analysts and investors, each including a question and answer session.1 The English-language webcast is scheduled for Thursday, July 30, 2026, at 8:00 am EDT, 1:00 pm BST, and 8:00 pm HKT.1 A separate Putonghua webcast will follow at 8:30 am HKT on Friday, July 31, 2026, which corresponds to 1:30 am BST and 8:30 pm EDT on Thursday, July 30, 2026.1
According to the filing, both webcasts will stream live on the company's website, with presentation materials posted shortly beforehand and a replay made available afterward.1
The filing also includes a brief company description. HUTCHMED describes itself as an innovative, commercial-stage biopharmaceutical company1 that, according to the release, is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases.1 The company states that its drug development history includes what it calls the "first three medicines marketed in China," one of which has also received regulatory approvals in markets including the US, Europe and Japan.1
The document was filed as a Form 6-K for the month of June 2026 and signed by Chief Financial Officer Johnny Cheng on June 30, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.